Dermata Therapeutics, Inc.

For the period ended Mar 31, 2025. Filed May 14, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 14, 2025

DRMA$0.77+0.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Cash Flows

	For the three months ended March 31,
2025 · 2024
Cash flows from operating activities:
Net loss		$(2,303,587)		$(3,134,262)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		37,189		587,234
Increase (decrease) in cash resulting from changes in:
Prepaid expenses and other current assets		86,579		94,424
Accounts payable		102,064		(43,482)
Accrued and other current liabilities		143,689		(208,368)
Total adjustments to reconcile net loss to net cash used in operations		369,521		429,808
Net cash used in operating activities		(1,934,066)		(2,704,454)
Cash flows from financing activities:
Proceeds from issuance of Common Stock, pre-funded warrants, and warrants, net of issuance costs		8,541,282		-
Proceeds from exercise of pre-funded warrants		977		-
Payment of prior period issuance costs		(50,495)		-
Net cash provided by financing activities		8,491,764		-
Net increase (decrease) in Cash and cash equivalents		6,557,698		(2,704,454)
Cash and cash equivalents at beginning of period		3,161,570		7,438,135
Cash and cash equivalents at end of period		$9,719,268		$4,733,681
Non-cash financing activities:
Issuance of abeyance shares	$	-		$(18)
January 2025 PIPE issuance costs in accounts payable		$79,102	$	-
March 2025 Warrant Inducement issuance costs in accounts payable		$456,631

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.